

DAFTAR PUSTAKA

1. Antono D, Hamonangani R. Dalam : Sudoyo AW, editors. Penyakit arteri perifer. Dalam ilmu penyakit dalam. Ed ke-6. Jakarta: Internal Publishing. 2016:1516–26.
2. Yang C, Kwak L, Ballew S, Garimella PS, Jaar B, Folsom AR, et al. Kidney function, bone-mineral metabolism markers, and future risk of peripheral artery disease. *Atherosclerosis*.2017;267:167–74.
3. Husin W, Hudaja O, Kristianto. Oklusi arteri perifer pada ekstremitas inferior. *JKM*.2006;6(1):40–53.
4. Thendria T, Toruan I, Natalia D. Hubungan antara hipertensi dan penyakit arteri perifer berdasarkan nilai ankle brachial index. *eJKI*.2014;2(1):37–43.
5. American College of Cardiology Foundation/ America Heart Association (ACCF/AHA). Pocket guideline : management of patient with peripheral artery disease (lower extremity, renal, mesenteric and abdominal aortic). *Am Coll Cardiol*.2011;58:2020–45.
6. Santosa A, Listiono D. Prediksi score ankle brachial index (ABI) ditinjau dari tanda gejala peripheral arterial disease (PAD). *Medisains*.2017;15(2):118–28.
7. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010 : a systematic review and analysis. *Lancet*.2013;382:1329–40.
8. Fowkes FGR, Low LP, Tuta S, Kozak J. Ankle- brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease. Results of the International AGATHA study.*Eur Heart J*.2006;27(15):1861–7.
9. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. *Lancet Glob Health*.2019;7:e1020–30.
10. Eraso L, Fukaya E, Mohler E, Bjorck M, Brodmann M, Czerny M, et al. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. *Eur J Prev Cardiol*. 2014;21(6):704–11.
11. Lefebvre K, Chevan J. The persistence of gender and racial disparities in vascular lower extremity amputation: an examination of HCUP-NIS data (2002-2011). *Vasc Med*. 2015;20(1):51–9.

12. Sigvant B, Lundin F, Wahlberg E, Ricco JB, Aboyans V, Bartelink ML, et al. The risk of disease progression in peripheral arterial disease in higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. *Eur J Vasc Endovasc Surg.*2016;51:395–403.
13. Penyakit Ginjal Kronik. Hasil Utama Riskesadas 2018. Badan Penelitian dan Pengembangan Kesehatan. Kementerian Kesehatan Republik Indonesia.2018. [Diakses 13 Januari 2020]. Diunduh dari : <http://www.depkes.go.id/resources/download/info-terkini-riskesadas-2018.pdf>
14. Sutarka N, Suwita K, Loekman JS, Sudhana W, Kandarini Y, Martadiani ED, dkk. Hubungan penyakit ginjal kronis predialisis dengan beberapa parameter penyakit aterosklerosis arteri karotis. *J Peny Dalam.* 2010;11(3):171–5.
15. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J. The chronic renal insufficiency cohort (CRIC) study : Design and Methods. *J Am Soc Nephrol.*2003;14:S148–53.
16. Garimella PS, Hart PD, O'Hare A, DeLoach S, Herzog CA, Hirsch AT. Peripheral artery disease and CKD : a focus on peripheral artery disease as a critical component of CKD care. *Am J Kidney Dis.*2012;60(4):641–54.
17. Lainscak M. Cardiovascular risk in chronic kidney disease. *J Int Fed Clin Chem.*2009;20:70–5.
18. Liew Y, Bartholomew J, Demirijan S, Michaels J, Schreiber M. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high risk population. *CJASN.*2008;3(4):1084–9.
19. Iparraguirre ST, Iranzo RM, Sanmamed RF, Garcia AR, Rodriguez EH, Casas JBG. Peripheral arterial disease and kidney failure : a frequent association. *Nefrologia.*2012;32(3):313–20.
20. Garimella PS, Hirsch AT. Peripheral artery disease and Chronic Kidney Disease : Clinical Synergy to Improve Outcomes. *Adv Chronic Kidney Dis.*2014;21(6):460–71.
21. O'Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. *Circulation.* 2004;109(3):320–3.

22. Laghari S, Ullah K, Masroor I, Butt G, Kifayat F. Prevalence of peripheral arterial disease diagnosed by ankle brachial index among chronic kidney disease patients in a tertiary care unit. *Saudi J Kidney Dis Transpl.*2015; 26 (5): 924–30.
23. Nelson AJ, Raggi P, Wolf M, Gold AM, Chertow GM, Roe MT. Targeting vascular calcification in chronic kidney disease. *JACC.*2020;5(5):398–412.
24. Wulandari DC, Widiana GR, Sufhana IW, Suwitra K. Hubungann antara produk kalsium x fosfat serum dengan penyakit arteri perifer pada pasien hemodialysis regular di RSUP Sanglah Denpasar. *J Peny Dalam.*2007;8:13–41.
25. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), *Kidney Int, Sup 7,1,2017.*
26. Valdivielso JM, Puyol DR, Pascual J, Barrios C, Lopez MB, Nino MDS, et al. Atherosclerosis in chronic kidney disease. *Arterioscler Tromb Vasc Biol.*2019;39:1938–66.
27. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39: S1–S266.
28. Quniby WY. Consequences of hyperphosphatemia in patients with end stage renal disease. *Kidney Int Suppl.*2004;90:8–12.
29. Wu CL, Tarng DC. Targeting uremic toxins to prevent peripheral vascular complications in chronic kidney disease. *Toxins.*2020;12:1–15.
30. Safnurbaiti DP, Andayani TM, Irijanto F. Analisis biaya dan nilai utilitas pasien hemodialisa yang diberikan terapi sevelamer karbonat. *Oceana Biomedicina Journal.* 2018;1(2):79–89.
31. Melisa, Andayani TM, Irijanto F. Pengaruh penggunaan terapi sevelamer terhadap kualitas hidup pasien hemodialisis yang dinilai menggunakan KDQOL. *The 5th URECOL PROCEEDING.*2017:427–39.
32. Katteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Taber SC, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. *Clin J Am Soc Nephrol.*2008;3:1125–30.
33. Abraham G, Kher V, Saxena S, Jayakumar M, Chafekar D, Pargaonkar P, et al. Sevelamer carbonate experience in Indian end stage renal disease patients. *India J Nephrol.*2012;22(3):189–92.

34. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39: S1–S266.
35. World Health Organization. Mortality and global health estimates : causes of death: Projections for 2015 – 2030; Projection of death rates. <http://apps.who.int/gho/data/node.main> (diunduh 8 januari 2020).
36. Riset Kesehatan Dasar (Riskesdas 2013) Laporan Nasional 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia.2013.
37. Prince SA, Wilson LM. Patofisiologi konsep klinis proses-proses penyakit. *EGC*.2005:867–75.
38. Coresh J, Turin TC, Matsushita K. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. *JAMA*.2014;311:2518–31.
39. Barry MB. *The Kidney*, 8 th Edition. Saunders Elsevier.2008;1784 –1807.
40. Song L. *Calcium and Bone Metabolism Indices*. Elsevier.2017;82:1– 47.
41. Moe S, Drueke T, Cunningham J. Definition, evaluation, and classification of renal osteodystrophy : a position statement from kidney disease : Improving Global Outcomes (KDIGO). *Kidney Int*.2006;69:1945–53.
42. Liew Y, Bartholomew J, Demirijan S, Michaels J, Schreiber M. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high risk population. *CJASN*.2008;3(4):1084–9.
43. Tenenhouse HS. Regulation of phosphorus homeostasis by type IIa/phosphate cotransporter. *Annu Rev Nutr*.2005;25:197–214.
44. Adragao T, Frazao J. Phosphate Balance in chronic kidney disease. *Port J Nephrol Hypert*.2012;26(2):149–56.
45. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: The killer of patients with chronic kidney disease. *J Am Soc Nephrol* 2009;20:1453–64.
46. Karwowski W, Naumnik B, Szczepanski M, Mysliwiec M. The mechanism of vascular calcification—A systematic review. *Med Sci Monit*.2012;18:RA1–11.

47. Cozzolino M, Dusso AS, Slatopolsky E. Role of Calcium-Phosphate Product and Bone-associated Proteins on Vascular Calcification in Renal Failure. *J Am Soc Nephrol*.2001;12:2511–16.
48. Cadth Issues In Emerging Health Technologies. New Technologies for the Treatment of Peripheral Artery Disease. *CADTH*.2018;1–9.
49. Rifkin DE, Ix JH, Wassel CL, Criqui MH, Allison MA. Renal artery calcification and mortality among clinically asymptomatic adults. *J Am Coll Cardiol*.2012;60:1079–85.
50. Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease : a collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/ AHA Task Force on Practice Guidelines. *Circulation*. 2006;113:e463–654.
51. Giachelli CM. Vascular calcification mechanism. *JASN*.2004;15(12):2959–64.
52. Josephs SC, Rowley HA, Rubin GD; for Writing Group 3. Atherosclerotic Peripheral Vascular Disease Symposium II. Vascular magnetic resonance and computed tomographic imaging. *Circulation*.2008;118:2837–44.
53. Weinberg I, Giri J, Calfon M, Hawkins BM, Weinberg MD, Margey R, Hannon K, Schainfeld RM, Jaff MR. Anatomic correlates of supra-normal ankle brachial indices. *Catheter Cardiovasc Intervent* 2013;81:1025–1030.
54. Minar E, Schilinger M. Peripheral vascular disease : Basic & Clinical Perspective. *Future Medicine*.2013:1–93.
55. McDermott MM. Role of the ankle brachial index. *Springer*.2019:5–19.
56. Hutchison AJ. Oral phosphate binders. *Kidney Int*.2009;75:906–14.
57. Chertow GM, Burke SK, Raggi P; for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int*.2002;62:245–52.
58. Ossareh S. Clinical and economic aspects of sevelamer therapy in end – stage renal disease patients. *Int J Nephro and Renovasc Dis*.2014;7:161–8.
59. Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, et al. Cardiovascular Effect of sevelamer instage 3 CKD. *J Am Soc*.2013;24:842 –52.

60. Barreto FC, Barreto DV, Massy ZA, Drueke TB. Strategies for phosphate control in patients with CKD. *Kidney Int Reports*.2019;4:1043–56.
61. Luo Y, Li X, Li J, Wang X, Xu Y, Qiao Y, et al. Peripheral arterial disease, chronic kidney disease, and mortality: the Chinese ankle brachial index cohort study. *Vascular Medicine*.2010;15(2):107–12.
62. Yang CP, Tsai CY, Yeh SHJ. The prevalence and correlated factors of peripheral artery disease in patients with chronic kidney disease. *J Intern Med Taiwan*.2010;21:48–55.
63. Chen J, Mohler ER, Garimella PS, Hamm L, Xie D, Kimmel S, et al. Ankle brachial index and subsequent cardiovascular disease risk in patients with chronic kidney disease. *Journal of American Heart Association*.2016;1-9.
64. Goldberg I, Krause I. The role of gender in chronic kidney disease. *Eou Medic J*.2016;1(2):58–64.
65. Wang JG, Shaw PA, Townsend RR, Anderson AH, Xie D, Wang X, et al. Sex differences in the incidence of peripheral artery disease (PAD) in the chronic renal insufficiency cohort (CRIC). *Circ Cardiovasc Qual Outcomes*. 2016;9(2):S86–93
66. Villablanca AC, Muthuvel J, Carole B. Atherosclerosis and sex hormone: current concept. *Clinical Science*.2010;119:493-513.
67. Mufti AI, Alsadiqi, Subki AH, Abushanab RH, Rashid M, Ocheltree, et al. Peripheral artery disease risk factors innJeddah, Saudia Arabia: a retrospective study. *Int J Gen Med*.2019;12:49–54.
68. Vavra AK, Melina RK. Women and peripheral arterial disease. *Women's Health*.2009;5(6):669–83.
69. Chen FA, Yang CY, Yang WC, Chen YJ, Yung Y, Li SY, et al. Ankle-brachial index is a powerful predicyor of renal outcome and cardiovascular events in patients with chronic kidney disease. *TSWJ*.2012;1–7.
70. Sohal PM, Bhagat A, Gupta A, Gupta D, Sandhu JS. Peripheral arterial disease in chronic kidney disease:a prospective clinical study. *IJCMAAS*.2015:165 – 70.
71. Wulandari NLIM, Sudaryati NLG, Widyantari SS. Hubungan kadar kalsium dan fosfor penderita gagal ginjal kronik dengan hemodialisa di laboratorium klinik prodia Denpasar. *Widya Biologi*.2021;12(01):34–47.

72. Asceric RR, Dimkovic NB, Trajkovic GZ, Ristic BS, Jankovic AN, Duric PS, et al. Prevalence, clinical characteristic, and predictors of peripheral arterial disease in hemodialysis patients : a cross-sectional study. *Nephro*.2019;20:1–9.
73. Guyton AC, Hall JE. Buku ajar fisiologi kedokteran. Ed ke-11. Jakarta:EGC.2008;231–7.
74. Nuraini B. Risk factors of hypertension. *J Majority*.2015;4(5):1–10.
75. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. *Am J Kidney Dis*.2019;74(1):120–31.
76. Olin JW, Sealove B. Peripheral artery disease: current insight into the disease and its diagnosis and management. *Mayo Clin Proc*.2010;85(7):678–92.
77. Pepine CJ, Handberg EM. The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors. *Clin Cardiol*.2001;24(1):V1–5.
78. Sarjana D, Isnanta R, Thamrin A. Correlation between cardiovascular risk factors with peripheral arterial disease in kidney failure patients undergoing hemodialysis for more than three months in Haji Adam Malik General Hospital Medan Year 2018. *IJRSM*.2019:58–64.
79. Chen SC, Lee WH, Hsu PC, Huang JC, Lee CS, Lin TH, et al. Association of body mass index and left ventricular mass index with abnormally low and high ankle-brachial indices in chronic kidney disease. *Hypertens Res*.2016;39:166–70.
80. Huang Y, Xu M, Xie L, Wang T, Huang X, Lv X, et al. Obesity and peripheral arterial disease : a Mendelian randomization analysis. *Atherosclerosis*. 2016;247:218–24.
81. Anthoni, Supriyadi R, Fatimah SN. Serum calcium levels in chronic kidney patient stratified by body mass index. *AMJ*.2019;6(2):55– 9.
82. Sundari LPR. Defisiensi vitamin D pada obesitas. *JSSF*.2018;6(1):1– 5
83. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. *Am J Clin Nutr*.2000;72(3):690 –3.
84. Rajagopalan S, Dellegratottaglie S, Furniss AL, Gillespie BW, Sataayathum S, Lameire N, et al. Peripheral arterial disease in patients with end-stage renal disease. *Circulation*.2006;114:1914–22.

85. Annisya N, Armelia L. Gambaran rerata kadar kalsium dan fosfor pada pasien yang menjalani hemodialisis di RS Anna Medika Bekasi. *J Prof Medika*.2018;12(1):24 – 9.
86. Ishioka K, Ohtake H, Moriya H, Mochida Y, Oka M, Maesato K, et al. High prevalence of peripheral arterial disease (PAD) in incident hemodialysis patient : screening by ankle – brachial index and skin perfusion pressure measurement. *BMC*.2018;4(27):1– 7.
87. Prasetyorini TP, Warida. Hubungan kadar kalium, kalsium, dan fosfor anorganik pada penderita gagal ginjal. *JITekl*.2015;3(1):1–11.
88. Yauri LF, Moeis ES, Pandelaki K. Gambaran hasil produk kalsium dan fosfor pada pasien PGK stadium V di ruang hemodialisis RSUP Prof.Dr.R.D.Kandou Manado.eCI.2016;4(2):3–6.
89. Joachim H, Kestenbaum B. Serum Phosphorus Concentrations and Aerial Stiffness among individuals with normal kidney function to moderate Kidney Disease in MESA.*JASN*.2008;4(3):609–15.
90. Vinuesa SGD, Ortega M, Martinez P, Goicoechea M, Campdera FG, Luno J. Subclinical peripheral arterial disease in patient with chronic kidney disease: Prevalence and related risk factors. *Kidney Int*.2005;67(93):S44 –7.
91. Guerrero A, Montes R, Terol JM, Peralta AG, Toro J, Naranjo M, et al. Peripheral arterial disease in patients with stage IV and V chronic renal failure. *Nephrol Dial Transplant*.2006;21:3525–31.
92. Kamath TP, Prasad R, Allison MA, Criqui A, Ix JH, Rifkin DE, et al. Association of ankle brachial and toe brachial indexes with mortality in patients with CKD.*Kidney Med*.2020;2(1):68–75.
93. Ix JH, Katz R, DeBoer IH, Kesrenbaum BR, Allison MA, Siscovick DS, et al. Association of chronic kidney disease with the spectrum of ankle brachial index the CHS (Cardiovascular Health Study). *J Am Coll Cardiol*.2009;54:1176–84.
94. Rastogi A.Sevelamer revisited : pleiotropic effects on endothelial and cardiovascular rsik factors in chronic kidney disease and end-stage renal disease. *Ther Adv Cardiovasc Dis*.2013;7(6):322–42